Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020

Ismail Ajjawi; Stacy Loeb; Matthew R Cooperberg; William J Catalona; Cary P Gross; Xiaomei Ma; Michael S Leapman

doi:10.1001/jama.2024.20580

Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020

JAMA. 2024 Dec 17;332(23):2033-2036. doi: 10.1001/jama.2024.20580.

Authors

Ismail Ajjawi¹, Stacy Loeb^{2

3}, Matthew R Cooperberg^{4

5}, William J Catalona⁶, Cary P Gross^{7

8}, Xiaomei Ma^{8

9}, Michael S Leapman^{8

10}

Affiliations

¹ Yale School of Medicine, New Haven, Connecticut.
² Department of Urology, New York University Langone Health, New York.
³ Manhattan Veterans Affairs Medical Center, New York, New York.
⁴ Department of Urology, University of California, San Francisco.
⁵ Department of Epidemiology and Biostatistics, University of California, San Francisco.
⁶ Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
⁷ Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
⁸ Yale Cancer Outcomes, Public Policy, and Effectiveness Research Center, New Haven, Connecticut.
⁹ Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut.
¹⁰ Department of Urology, Yale School of Medicine, New Haven, Connecticut.

PMID: 39565605
PMCID: PMC11579888 (available on 2025-05-20)
DOI: 10.1001/jama.2024.20580

No abstract available

Plain language summary

This cross-sectional study evaluates trends and factors associated with selecting active surveillance or watchful waiting among individuals with intermediate-risk prostate cancer.